Smith & Nephew’s (SN) Neutral Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. restated their neutral rating on shares of Smith & Nephew (LON:SN) in a report released on Tuesday. They currently have a GBX 1,477 ($19.30) price target on the stock.
SN has been the subject of several other research reports. Deutsche Bank raised Smith & Nephew to a hold rating and lifted their price objective for the stock from GBX 1,200 ($15.68) to GBX 1,350 ($17.64) in a report on Monday, December 10th. HSBC lowered Smith & Nephew to a hold rating and lifted their price objective for the stock from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a report on Tuesday, October 16th. Berenberg Bank lifted their price objective on Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and gave the stock a hold rating in a report on Friday, November 2nd. UBS Group reaffirmed a neutral rating on shares of Smith & Nephew in a report on Friday, October 26th. Finally, Morgan Stanley upgraded Smith & Nephew to an overweight rating and lifted their target price for the company from GBX 1,457 ($19.04) to GBX 1,692 ($22.11) in a research report on Monday, December 10th. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Smith & Nephew currently has an average rating of Hold and an average target price of GBX 1,457.67 ($19.05).
Shares of SN opened at GBX 1,463.50 ($19.12) on Tuesday. Smith & Nephew has a one year low of GBX 1,173 ($15.33) and a one year high of GBX 1,442 ($18.84).
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Recommended Story: Why is the LIBOR significant?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.